P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2019

Home/P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2019

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2019

Drug Pipeline, Pharma & Healthcare

Publication ID:

GMD0319075

Publication Date:

March 29, 2019

Pages:

Publisher:

Global Markets Direct

Region:

Global

$3,500.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2019

Summary

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - P2X purinoceptor 7 is a protein encoded by the P2RX7 gene. It acts as receptor for ATP that acts as a ligand-gated ion channel. It is responsible for ATP-dependent lysis of macrophages through the formation of membrane pores permeable to large molecules.

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) pipeline Target constitutes close to 15 molecules. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 1, 3 and 5 respectively. Report covers products from therapy areas Central Nervous System, Oncology, Immunology, Genetic Disorders and Gastrointestinal which include indications Epilepsy, Inflammation, Neuropathic Pain (Neuralgia), Breast Cancer, Charcot-Marie-Tooth Disease Type I A, Colorectal Cancer, Depression, Lung Cancer, Multiple Sclerosis, Prostate Cancer, Alzheimer's Disease, Basal Cell Carcinoma (Basal Cell Epithelioma), Bipolar Disorder (Manic Depression), Duchenne Muscular Dystrophy, Hematological Tumor, Inflammatory Bowel Disease, Major Depressive Disorder, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Prostate Cancer, Neuroinflammation, Pain and Solid Tumor.

The latest report P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2019, outlays comprehensive information on the P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)
- The report reviews P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics and enlists all their major and minor projects
- The report assesses P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 7 (P2Z Receptor or P2RX7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Overview
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Companies Involved in Therapeutics Development
Affectis Pharmaceuticals AG
Asahi Kasei Pharma Corp
Axxam SpA
Biosceptre International Ltd
Evotec AG
Johnson & Johnson
Lead Discovery Center GmbH
Suven Life Sciences Ltd
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Drug Profiles
AFC-5128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKP-23494954 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-010t - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-03s - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-06v - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-07v - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EVT-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-5446 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-55308942 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small molecule to Antagonize P2X7 for Multiple Sclerosis and Epilepsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize P2X7 Receptor for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize P2RX7 for CNS Disorders, Autoimmune Disorders and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize P2X7 for Inflammation and Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize P2X7 for Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Dormant Products
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Discontinued Products
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Product Development Milestones
Featured News & Press Releases
Nov 14, 2018: Update on phase I trial of vaccine BIL06v
Aug 21, 2018: Initiation of Biosceptre’s phase 1 clinical trial for first-in-class oncology vaccine BIL06v
Mar 03, 2017: Biosceptre publishes a clinical study of topical drug BIL010t as therapy for Basal cell carcinoma
Dec 18, 2014: Alzheimer’s Drug Discovery Foundation And Axxam Continue Their Successful Collaboration To Develop Novel Therapeutics For Alzheimer’s Disease
Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma
Jan 25, 2012: Affectis Receives European Patent For AFC-5128 And Other P2X7 Antagonists
Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT 401
Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
List of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Affectis Pharmaceuticals AG, H1 2019
Pipeline by Asahi Kasei Pharma Corp, H1 2019
Pipeline by Axxam SpA, H1 2019
Pipeline by Biosceptre International Ltd, H1 2019
Pipeline by Evotec AG, H1 2019
Pipeline by Johnson & Johnson, H1 2019
Pipeline by Lead Discovery Center GmbH, H1 2019
Pipeline by Suven Life Sciences Ltd, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Discontinued Products, H1 2019

List of Figures
List of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

Companies Covered

Affectis Pharmaceuticals AG
Asahi Kasei Pharma Corp
Axxam SpA
Biosceptre International Ltd
Evotec AG
Johnson & Johnson
Lead Discovery Center GmbH
Suven Life Sciences Ltd

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".